<DOC>
	<DOC>NCT01957579</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.</brief_summary>
	<brief_title>A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Japanese men or women at least 20 years of age Histologically confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL, or MM. Karnofsky Performance Status ≥70; Life expectancy of ≥12 weeks Any available standard line of therapy known to be lifeprolonging or lifesaving Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer Previous therapy directed against CD19, such as monoclonal antibodies or MAb conjugates</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>advanced</keyword>
	<keyword>B cell malignancies</keyword>
	<keyword>dose escalation</keyword>
	<keyword>CD19</keyword>
	<keyword>Japanese</keyword>
</DOC>